Overcoming reprogramming resistance of Fanconi anemia cells. - Wikidata - awgldk - TriplyDB

Overcoming reprogramming resistance of Fanconi anemia cells.

Overcoming reprogramming resistance of Fanconi anemia cells.

http://www.wikidata.org/entity/Q36015202

about

Molecular pathogenesis and clinical management of Fanconi anemia Hallmarks of progeroid syndromes: lessons from mice and reprogrammed cells hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine Progress and obstacles towards generating hematopoietic stem cells from pluripotent stem cells Cellular reprogramming: a small molecule perspective Modelling human disease with pluripotent stem cells Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG)Modeling Human Bone Marrow Failure Syndromes Using Pluripotent Stem Cells and Genome Engineering Fanconi anaemia and the repair of Watson and Crick DNA crosslinks JNK/SAPK Signaling Is Essential for Efficient Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells Hypersensitivity of primordial germ cells to compromised replication-associated DNA repair involves ATM-p53-p21 signaling Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells Induced Pluripotent Stem Cells: Global Research Trends.The developmental potential of iPSCs is greatly influenced by reprogramming factor selection High-risk human papillomavirus E6 protein promotes reprogramming of Fanconi anemia patient cells through repression of p53 but does not allow for sustained growth of induced pluripotent stem cells.Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state.A human iPSC model of Ligase IV deficiency reveals an important role for NHEJ-mediated-DSB repair in the survival and genomic stability of induced pluripotent stem cells and emerging haematopoietic progenitors.Genomic editing tools to model human diseases with isogenic pluripotent stem cells.Stem cells: the pursuit of genomic stability.Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs Small molecule screening in human induced pluripotent stem cell-derived terminal cell types.Rescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model.Comparing ESC and iPSC-Based Models for Human Genetic Disorders Modeling xeroderma pigmentosum associated neurological pathologies with patients-derived iPSCs Disrupted Signaling through the Fanconi Anemia Pathway Leads to Dysfunctional Hematopoietic Stem Cell Biology: Underlying Mechanisms and Potential Therapeutic Strategies.New lessons learned from disease modeling with induced pluripotent stem cells.Mechanisms underlying the formation of induced pluripotent stem cells.Overcoming Pluripotent Stem Cell Dependence on the Repair of Endogenous DNA Damage Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk Concurrent progress of reprogramming and gene correction to overcome therapeutic limitation of mutant ALK2-iPSC.Phenotypic correction of Fanconi anemia cells in the murine bone marrow after carrier cell mediated delivery of lentiviral vector.Hematopoietic defects and iPSC disease modeling: lessons learned.Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors.BMP-SMAD-ID promotes reprogramming to pluripotency by inhibiting p16/INK4A-dependent senescence.Integrating Gene Correction in the Reprogramming and Transdifferentiation Processes: A One-Step Strategy to Overcome Stem Cell-Based Gene Therapy Limitations.Concise Review: Getting to the Core of Inherited Bone Marrow Failures.Current status of drug screening and disease modelling in human pluripotent stem cells.Technological overview of iPS induction from human adult somatic cells.Genetic instability of modified stem cells - a first step towards malignant transformation?

P2860

Q24621696-7B2D83D2-73A8-47A2-B342-2BD7D5A08394 Q26740026-C26D9BD8-25E6-4DC3-921E-311F1C03766D Q26751506-361E3405-DCE4-4786-9BB0-0CA1FA4ECF9C Q26824479-70A3FEC6-84DF-473C-B44C-E72E724C5420 Q26829509-E178612C-885B-48C6-9979-36DA2DA0C909 Q26864380-6CDD992A-AFE3-4BE1-98EF-31E03A8E8F81 Q27311626-92286300-D985-4B9D-B961-AC1BF888A868 Q28083303-32D2DC04-9039-41BE-8832-9E855C6A3E16 Q28283549-B5757B06-C7BA-4566-9BC8-F93A00852305 Q28830469-B088BF3B-BBAA-4F2B-885A-DAC6253EE346 Q33838956-581D521B-1F40-4F3E-BF25-CD954C151DDA Q33880788-51912DE8-638F-44C1-827B-A208414724EF Q33894805-A24C0C7A-57F1-473E-8D8A-B5AF0FF3644B Q33914515-BDDFFE59-A994-47EB-813D-ABDA6418B255 Q34222768-2466E978-0B30-47B2-A0E1-828843BD837A Q34261778-D3F734FD-FCFE-496E-81F2-B8DDB7DF220D Q34332168-3F1F1522-57CE-492D-8FDD-C1A70103C476 Q34347694-D6B09B18-A9AC-4524-BE37-6E3FDA57385E Q34437293-BFBEFB5F-5824-44CB-99C9-E62A354790E4 Q34685564-6B98868C-9EF4-4989-8849-7F2CA3DDFC83 Q34918292-B5667646-9C3A-4875-B15B-CBA50F8841A9 Q35074117-DEC4B4F9-3A8B-4874-8700-2DC32F9A5E92 Q35637089-A29CF13D-A8CE-48F2-8ED6-EB3E35D8C4EB Q35750530-C557EFCD-00A7-4DE4-8EA8-6C0D8E84A86E Q35923231-3292E2A9-4F87-4138-8475-1B64DEC74309 Q36004703-4ED9C4B1-45B3-4655-A1AA-1DC9C0297D2A Q36374130-F4593C3D-CF59-4AD4-B81E-5E1BF2193D17 Q36469676-6132671D-2696-4696-A4BC-E3B13169BD97 Q36480583-D3595220-01AC-4060-B139-B72343039EFE Q36861412-135845C4-95FD-429A-8741-757D7747A66F Q37057699-C49CA673-1AF9-4CCE-A85E-A58A011CC24B Q37424081-3FF295F1-DCF1-471C-B153-8FE7D84F7BC8 Q37462869-C27F2779-9F38-4B05-9439-50DE1F233345 Q37462880-33C4CC38-869E-49AC-9604-F08FA0754A83 Q37469332-61CDE19D-74B5-4D21-82CE-14ED75682529 Q37542688-C2BE203C-36E6-4392-B5C7-F3D05882DEAC Q37633372-DC810710-1168-4B77-A2F9-DC2347EFCF03 Q38034129-DC647653-9DA2-4631-8695-783367B9A964 Q38074176-C9E8EB56-FD50-4C6B-9E50-AFB3DF43E605 Q38106717-55465BC7-3073-44BC-9C11-BB23AD0756AC

P2860

Overcoming reprogramming resistance of Fanconi anemia cells.

http://www.wikidata.org/entity/Q36015202

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Overcoming reprogramming resistance of Fanconi anemia cells.

@ast

Overcoming reprogramming resistance of Fanconi anemia cells.

@en

type

label

Overcoming reprogramming resistance of Fanconi anemia cells.

@ast

Overcoming reprogramming resistance of Fanconi anemia cells.

@en

altLabel

Overcoming reprogramming resistance of Fanconi anemia cells

@en

prefLabel

Overcoming reprogramming resistance of Fanconi anemia cells.

@ast

Overcoming reprogramming resistance of Fanconi anemia cells.

@en

P1433

Q36015202-0973D79E-F291-4A3E-8A77-EFF2AE598D4B

P1476

Q36015202-B161F224-15E1-4B9A-A63C-3823BEFD6C41

P2093

Q36015202-1FD09612-B00D-4366-95BA-097A9B991BA8

Q36015202-20E7A31E-EE79-4108-90DE-96EC3A1036AA

Q36015202-21140988-2EF7-492C-9BF3-6F8E0BF9315F

Q36015202-30F4FE04-0951-4329-937C-4982A0ADFDF6

Q36015202-4CE14B5F-DC24-4B8E-A820-8026C35AF22B

Q36015202-6E8E8155-D253-4C0A-B39B-F5C595CFC097

Q36015202-8E61E047-F6BD-4263-938C-EC11D89CD981

Q36015202-A2BE9126-67EC-4786-858F-218DC7B5E471

Q36015202-A60E98C0-0C00-4E8D-8E6C-673AC15B7F39

Q36015202-C5A498C8-4F10-46B9-B017-175229E070C6

P2860

Q36015202-02D6D04A-9BCD-4A62-8F8F-00B338F6F087

Q36015202-0337D1AF-0DC0-4BD3-AA30-1FFE179CBC00

Q36015202-04DF6062-16CF-49BC-86AF-2EFDC911C155

Q36015202-05DF0795-4FE5-488A-8123-8D58F0A2A6C0

Q36015202-07C97B4C-D8D4-41E5-94A7-32F74C6FEA72

Q36015202-10776F2C-38AE-4CA3-B9C7-8760802A3F99

Q36015202-1ACC7BF5-1359-4340-868E-07403251E239

Q36015202-21B6D8FA-552F-4806-B9AD-2E0F5D37FDB7

Q36015202-2892F26F-CB3E-4A16-8733-E3CA3E1A8D88

Q36015202-2B07FA1A-4C05-4048-8D71-8E6D26C540EB

P304

Q36015202-10BDE840-D92C-4A5E-9CC5-464E335B9720

P31

Q36015202-F64FBEFC-4F27-433F-8A1E-37D43832DE00

P356

Q36015202-63B85D98-FA52-4123-B3C1-0D5B0FE395F2

P407

Q36015202-2002E6D8-7A84-4F77-B263-F41F91A5A9FC

P433

Q36015202-9FB97850-CED2-4660-AA15-E3DC935D0412

P478

Q36015202-FDE68958-7D20-469F-92E0-18D7B546266D

P50

Q36015202-581BEACB-D028-4AE5-BB30-EC4A62A91E14

Q36015202-F70DCDA6-4BB7-40ED-AEFB-4B031CE0464E

P577

Q36015202-3264C264-3111-49F1-A033-E21007CD2958

P5875

Q36015202-AF4BC6CE-628B-4628-B180-5A0B613AE794

P698

Q36015202-2D54A8FE-3C12-4C1A-BCE7-290539B0A042

P932

Q36015202-A189A4EE-3DC5-4984-B86C-9FF0F411575F

P356

BLOOD-2012-02-408674

P1433

P1476

Overcoming reprogramming resistance of Fanconi anemia cells.

@en

P2093

Alan D'Andrea

http://www.w3.org/2001/XMLSchema#string

Alexander L Devine

http://www.w3.org/2001/XMLSchema#string

Chad E Harris

http://www.w3.org/2001/XMLSchema#string

David A Williams

http://www.w3.org/2001/XMLSchema#string

Elke Grassman

http://www.w3.org/2001/XMLSchema#string

In-Hyun Park

http://www.w3.org/2001/XMLSchema#string

Kalindi Parmar

http://www.w3.org/2001/XMLSchema#string

Kelly Strait

http://www.w3.org/2001/XMLSchema#string

Kristina M Brumme

http://www.w3.org/2001/XMLSchema#string

Lars U W Müller

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of the SLX4 gene in Fanconi anemia

How the fanconi anemia pathway guards the genome

Direct cell reprogramming is a stochastic process amenable to acceleration

Generation of germline-competent induced pluripotent stem cells

Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC)

The emerging genetic and molecular basis of Fanconi anaemia

Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia

Immortalization eliminates a roadblock during cellular reprogramming into iPS cells

Oxidative stress/damage induces multimerization and interaction of Fanconi anemia proteins

Reprogramming of human somatic cells to pluripotency with defined factors

P304

5449-5457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-02-408674

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

George Q. Daley

P577

2012-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221868036

http://www.w3.org/2001/XMLSchema#string

P698

22371882

http://www.w3.org/2001/XMLSchema#string

P932

3369681

http://www.w3.org/2001/XMLSchema#string